Alzamend Neuro (ALZN) Regains Nasdaq Compliance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
July 31, 2024 8:00 AM EDTATLANTA--(BUSINESS WIRE)-- Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), today announced that it has received a notification letter (the Compliance Notice) from the Listing Qualifications... More
